Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say
Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.
You may also be interested in...
With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.
Aetna’s Kolodziej and Anthem’s Malin discuss how the American Society for Clinical Oncology’s framework for valuing cancer drugs might influence payer decision-making and drug access.
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.